secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aspire Biopharma Holdings, Inc. (ASBP)
CIK:        0001847345
Form:       8-K
Filed at:   2025-09-26T23:59:59+00:00
Accession:  0001493152-25-015773
Event type: other_material
Sentiment:  negative
Materiality: 0.70
Item codes: 3.02, 4.01
LLM model:  deepseek-v4-flash:cloud@v2

Aspire Biopharma dismisses auditor Bush, appoints Turner Stone; gets $1M funding tranche
--------------------------------------------------------------------------------

- Dismissed Bush & Associates CPA as independent auditor effective Sept 22, 2025; 2024 audit included going concern explanatory paragraph.
- Appointed Turner Stone & Co. as new independent auditor for FY 2025, effective Sept 22, 2025.
- No disagreements with Bush; material weaknesses in internal control over financial reporting were disclosed.
- Received $1M second tranche funding under Securities Purchase Agreement for notes with aggregate principal $9.6875M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1847345/000149315225015773/0001493152-25-015773-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1847345/000149315225015773/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-015773

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer